The preparation and pharmacologic activity of two new hybrid LTB(4) re
ceptor antagonists, 1 and 2 (LY282210), are reported. These compounds
are among the most potent in vitro LTB(4) receptor antagonists yet des
cribed, and add new insight into the critical pharmacophores of the LT
B(4) receptor.